The American pharmaceutical company is again increasing its annual targets. The targeted sales should almost double compared to the previous year.
The US pharmaceutical company Pfizer continues to benefit strongly from the Covid-19 vaccine developed with its German partner Biontech. But Pfizer also grew outside of the business with the corona vaccine Comirnaty in the past quarter.
The management around CEO Albert Bourla raised its annual targets again. In 2021, sales are now expected to almost double compared to the previous year to 81 to 82 billion dollars (up to 70.8 billion euros), as the company announced on Tuesday.
Pfizer expects the corona vaccine to make an even greater contribution than before, as further delivery agreements have now been made with buyer countries. Comirnaty is likely to contribute around 36 billion dollars instead of the previously forecast around 33.5 billion dollars. The earnings per share (EPS) adjusted for one-off effects should also increase more strongly than previously expected by the Group.
In the past quarter, Pfizer more than doubled sales to $ 24.1 billion. The bottom line was a profit of $ 8.1 billion. In the same quarter of the previous year it was just under 1.5 billion.
Source From: Stern
Jane Stock is a technology author, who has written for 24 Hours World. She writes about the latest in technology news and trends, and is always on the lookout for new and innovative ways to improve his audience’s experience.
